## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.12 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($96.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY)**
- Source: Simply Wall Street | 20251218T214001 | Bullish | Relevance: 100%
- Incyte recently secured European Commission approval for Minjuvi, broadening its oncology presence with the first chemotherapy-free, dual-targeted immunotherapy for follicular lymphoma. This development strengthens Incyte's oncology portfolio, but the company's investment narrative still hinges on the performance of Opzelura and Jakafi, while facing risks from potential revenue erosion of the latter. Investors should consider how this approval impacts Incyte's overall financial health and future pipeline potential.

**2. Incyte to Present at Upcoming Investor Conference**
- Source: Business Wire | 20251218T130825 | Somewhat-Bullish | Relevance: 100%
- Incyte (Nasdaq: INCY) announced it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026, at 8:15 am (PST). The presentation will be available via live webcast and replay on Investor.Incyte.com. Incyte is a global biopharmaceutical company focusing on oncology and inflammation & autoimmunity.

**3. Incyte Announces European Commission Approval of MinjuviÂ® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma**
- Source: Business Wire | 20251217T160754 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL). This first-of-its-kind chemotherapy-free dual-targeted immunotherapy offers a new treatment option for eligible patients. The approval is based on Phase 3 inMIND trial data demonstrating significantly improved progression-free survival compared to placebo.

**4. Incyte Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251219T163000 | Bullish | Relevance: 100%
- Incyte Corp. (INCY) shares rose 5.53% to $102.69 on Friday, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a strong trading day. The stock closed 6.03% below its 52-week high of $109.28.

**5. Michael James Morrissey Sells 54,008 Shares of Incyte (NASDAQ:INCY) Stock**
- Source: MarketBeat | 20251218T222614 | Neutral | Relevance: 100%
- Michael James Morrissey, EVP of Incyte Corporation, sold a significant portion of his holdings, including 54,008 shares on December 16th and an additional 4,323 shares on December 17th, reducing his ownership by about 62.92%. These sales occurred amidst strong quarterly results for Incyte, which reported beating analyst EPS and revenue estimates. Despite institutional ownership of nearly 97%, analyst sentiment for the stock is mixed, with an average "Hold" rating.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.08M) |
| Sells | 17 ($23.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $24M sold (17 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Momentum building: MRS_20 improving +4.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.2B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 13.3 |
| Current P/E | 15.0 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -2.2% to 2.1% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 at 2.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.15% (CS: 70) | Neutral |
| RSI_14 | 58.2 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 1.319x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $102.69
- **Stop Loss:** $96.07 (6.4% risk)
- **Target:** $115.93 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 181
- **Position Value:** $18,586.89
- **Portfolio %:** 18.59%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*